ALK mutations in paediatric tumours

Dr Turner speaks with ecancer at Childhood Cancer 2016 about her work, made possible by a project grant from Children with Cancer UK.

She describes the role of ALK activity in the aetiology anaplastic large cell lymphoma, and as a target for paediatric therapies following the success of crizotinib in treating ALK lung cancer.

Considering the mechanisms of resistance, Dr Turner outlines how her research into screening for 'bypass tracks' might circumvent resistance in childhood disease.